Expression and functional characterization of LRRC4, a novel brain-specific member of the LRR superfamily  by Zhang, Qiuhong et al.
FEBS Letters 579 (2005) 3674–3682 FEBS 29683Expression and functional characterization of LRRC4, a novel
brain-speciﬁc member of the LRR superfamily
Qiuhong Zhanga,1, Jieru Wanga,b,1, Songqing Fana, Lili Wanga, Li Caoa, Ke Tanga, Cong Penga,
Zheng Lia, Weifang Lia, Kai Gana, Zhongqi Liua, Xiaoling Lia, Shourong Shenc, Guiyuan Lia,*
a Cancer Research Institute, Central South University, Changsha 410078, Hunan, Peoples Republic of China
b School of Public Health, Central South University, Changsha 410078, Hunan, Peoples Republic of China
c The Third Aﬃliated Hospital of Xiang Ya School of Medicine, Central South University, Changsha 410078, Hunan, Peoples Republic of China
Received 28 February 2005; revised 20 April 2005; accepted 9 May 2005
Available online 13 June 2005
Edited by Lukas HuberAbstract LRRC4, a novel member of LRR superfamily
thought to be involved in development and tumorigenesis of the
nervous tissue, has the potential to suppress tumorigenesis and
cell proliferation of U251MG cells. This study aimed at reveal-
ing the correlation between expression of LRRC4 and the main-
tenance of normal function and tumorigenesis suppression within
the central nervous system. We systematically analyzed the
expression and tissue distributions of the gene in tissues. Results
showed that LRRC4 expression was limited to normal adult
brain, both in human and in mouse, and exhibited a develop-
ment-regulated pattern, but was down-regulated in brain tumor
tissues and U251MG cell line. Furthermore, dynamic alterations
in gene expression associated with cell cycle progression were
investigated by using Tet-on system. Results showed that
LRRC4 induced a cell cycle delay at the late G1 phase, probably
through the alteration of the expression of diﬀerent cell cycle
regulating proteins responsible for mediating G1-S progression,
such as p21Waf1/Cip1 and p27Kip1, Cdk2 and PCNA, p-ERK1/2.
These ﬁndings suggest that LRRC4 may play an important role
in maintaining normal function and suppressing tumorigenesis in
the central nervous system.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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A growing body of evidences indicates that the long arm of
human chromosome 7 is associated with many types of neopla-Abbreviations: LRRC4, leucine rich repeat containing 4; LRR, leucine
rich repeat; LOH, loss of heterozygosity; ESTs, expressed sequence
tags; CDKI, cyclin-dependent kinase inhibitor; CDK, cyclin-depen-
dent kinase; Tet, tetracycline; ORF, open reading frame; Dox, doxy-
cycline; GAC1, glioma ampliﬁed on chromosome 1 protein; LGI-1,
leucine-rich gene, glioma-inactivated-1; ISLR, immunoglobulin super-
family containing LRR; NGL-1, netrin G1 ligand; PCNA, proliferat-
ing-cell nuclear antigen; ERK1/2, extracellular receptor-activated
kinases 1/2; MAPK, mitogen-activated protein kinase; PBS, phos-
phate-buﬀered saline; FBS, fetal bovine serum
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mosome 7q are frequently encountered in malignant myeloid
disorders as well as in head and neck, breast, prostate, ovarian,
colon, gastric, pancreatic, and renal cell carcinomas [1,2]. Our
previous studies demonstrate there is the LOH on chromo-
some 7q31-ter in nasopharyngeal carcinoma [3,4]. Introduc-
tion of an intact copy of human chromosome 7 restored
senescence of immortalized human ﬁbroblast cell lines harbor-
ing LOH of markers within 7q31-32 and inhibited the tumor-
igenic phenotype of a murine squamous cell carcinoma cell line
[5]. These studies indicated that one or more tumor suppressor
genes are located at chromosome 7q.
Employing an EST-mediated screening strategy [6], we have
identiﬁed a potential tumor suppressor gene encoding a leu-
cine-rich repeat (LRR) protein on 7q31-ter designated as
LRRC4 (GenBank accession number is AF196976). LRRC4
speciﬁcally expresses in human normal brain tissues and is
down-regulated in primary brain tumor biopsies, especially
in gliomas [7]; it has the potential of suppressing U251MG
tumorigenesis and cell proliferation [8]. LRR domains are
known to mediate protein–protein interactions and cell adhe-
sion. Many of LRR containing proteins contribute to the dif-
ferentiation and development of a variety of tissues as
receptor-binding ligand, particularly to the nervous tissue
[9,10]. On the basis of the structural property, expression pat-
tern, and map location, LRRC4 may be a candidate tumor
suppressor gene on 7q31-32.
To further verify and demonstrate the functional character-
ization of LRRC4, we systematically analyzed the localization
of this protein in the cells and its mRNA distribution in tissues;
we also investigated the potential molecular mechanism of
LRRC4 on inhibiting glioma tumorigenesis by ﬂow cytometry
and Western blot analysis using Tet on system [11,12].2. Materials and methods
2.1. Computer-assisted analysis
Database searches were carried out using BLAST and Swiss-Prot.
Motif searches were performed with PSORT and SMART program.
Comparison of sequence was carried out using ClustalW (www.ebi.a-
c.uk/clustalw) and BOXSHADE (http://bioweb.pasteur.fr/seqanal/
interfaces/boxshade). All bioinformatics tools including the open read-
ing frame (ORF) identiﬁcation in the paper could be found at the
NCBI (National Center for Biotechnology Information) server
(www.ncbi.nlm.nih.gov) and molecular biology server of the Swiss
Institute of Bioinformatics (www.expasy.ch).blished by Elsevier B.V. All rights reserved.
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Total RNA was extracted using Trizol reagent according to the
guide of manufacturer (Gibco-BRL). After being treated with
DNase-I, 1–2 lg of total RNA was reverse transcribed with oligo
(dT) using cDNA synthesis kit (Promega). The subsequent PCRs were
performed using Taq polymerase and the buﬀer (Promega) supplied
with 0.2 mM dNTPs and 0.2 uM primers. Primers corresponding to
the ESTs, human LRRC4 and its mouse homology sequence were cho-
sen by using Primer 3 (www-genome.wi.mit.edu). A housekeeping
gene, GAPDH was ampliﬁed as internal control to normalize the rela-
tive levels of the cDNA. The reaction products were analyzed on 1.5%
agarose gels.
2.3. Northern blot analysis
Human MTN blots containing 2 lg of polyA RNA per lane from 16
diﬀerent human tissues and 8 diﬀerent brain tissues were obtained from
BD Clontech. The 1576 bp LRRC4 cDNA was excised from
I.M.A.G.E consortium clone 51970, gel-puriﬁed, and labeled with
[a-32P] dCTP using the Random prime kit (Promega). Hybridization
was carried out at 68 C overnight in Express Hyb (Clontech). Member
was washed at increasing stringency up to a ﬁnal wash of 1· SSC, 0.1%
(w/v) SDS at 65 C. The membranes were subsequently re-hybridized
with b-actin probe.
2.4. In situ hybridization
The probe, LRRC4-cDNA, was labeled with digoxigenin-11-dUTP
by random priming according to the protocol of the manufacturer
(Boehinger Mannheim, Indianapolis, IN). The ISH detection methods
have been previously described with minor modiﬁcations [13]. Brieﬂy,
5-lm-thick sections were deparaﬃnized, rehydrated, digested with
2.0 mg/L proteinase K at 37 C for 15 min, and dehydrated. The slides
were incubated with prehybridization solution at 37 C for 2 h and
hybridized with LRRC4 probe 37 C overnight before being washed
with graded saturated solutions of sodium citrate and treated with
anti-digoxigenin horseradish peroxidase Fab fragments (anti-DIG-
POD). The color was brought out by the 3-amino-9-ethylcarbazole
(AEC) and counterstained with hematoxylin.
2.5. Construction of expression vectors for LRRC4 and transient
transfection
The 1962 bp full length coding region of LRRC4 cDNA was ampli-
ﬁed by PCR with a forward primer (5 0 cgtggatccatgaagctcttgggcag 3 0)
and a reverse primer (5 0 cgggaattctcatatttgagtttcctg 3 0) using brain
cDNA library as template. The PCR ampliﬁcation was performed
for 30 cycles of denaturation (94 C, 30 s), annealing and extension
(70 C, 4 min), using the advantage2 PCR kit. The PCR-ampliﬁed
product was then subcloned into the pGEM-T Easy vector. The full
length-coding region was obtained by EcoRI digestion of pGEM-T
Easy-LRRC4 and subcloned into the EcoRI site of the pEGFP-C1
expression vector. After being transformed into JM109 (E. coli) and
identiﬁed by sequencing, the pEGFP-C1-LRRC4 fusion plasmid was
transiently introduced into U251MG cell by liposome transfection.
Localization of fusion protein was observed under the ﬂuorescence
microscope (Olympus).
2.6. Generation of U251MG Tet-on cell lines
U251MG cells were purchased from American Center for Type Cul-
ture Collection (ATCC). U251MG Tet-on Cells, which are stably
transfected with pTetOn (Clontech) and a G418-resistance plasmid,
were maintained in RMPI 1640 (Invitrogen) supplemented with 10%
FBS (Clontech)/100 units/ml penicillin/20 units/ml streptomycin/
800 mg/L G418 (Sigma). Then clones were screened by the luciferase
activity measured before and after doxycycline induction using scintil-
lation counting (Germany).
2.7. Generation of U251MG Tet-on cell lines expressing LRRC4
The doxycycline-inducible LRRC4 expression plasmid pTRE-2hyg-
LRRC4 was constructed by inserting the LRRC4 coding sequence into
NotI site of vector pTRE-2hyg (Clontech). To generate stable cell lines,
U251MG Tet-On cells were transfected with pTRE-2hyg-LRRC4.
Each culture was divided into the plates 2 days later, grown for an
additional 24 h, and then subjected to selection with 300 mg/L hygro-
mycin (Calbiochem)/G418 (Sigma). Resulting colonies were screenedfor LRRC4 expression by semi-quantitative RT-PCR using avian mye-
loblastosis virus reverse transcriptase system (Promega) and Northern
blot. Two positive U251MG Tet-on cell lines expressing LRRC4 cell
clones were selected to develop the following experiments. Primer
and probe sequences were chosen using Primer 3 (www-genome.wi.
mit.edu). The LRRC4 cDNA from stably transfected cell lines was
ampliﬁed by using a forward primer (5 0 ttggcccacaataacctctc 3 0) and
a reverse primer (5 0 acaggcttgtactttcgcgt 3 0). As an internal control,
b-actin was analyzed in parallel by using a forward primer (5 0 tccgtgga-
gaagagctacga 3 0) and a reverse primer (5 0 gtacttgagctcagaaggag 3 0).
2.8. Flow cytometry analysis
Cells were seeded 2 · 105 cells in 75-ml cell culture Petri ﬂasks. After
24 h, the cells were treated with 0.5 lM nocodazole for 7 or 24 h and
then trypsinized, washed, and ﬁxed with 70% ice-cold ethanol at
4 C for 30 min. After two washes in ice-cold PBS, the cells were incu-
bated with 100 mg/L propidium iodide (PI) (Sigma) plus 100 mg/L
RNase overnight at 4 C and analyzed by Flow cytometry using a
488-nm Argon laser and FL2-A detection line. DNA content fre-
quency histograms were deconvoluted using MODFIT LT software
(Verity, Topsham, ME). Values were expressed as mean and error
deviation of three independent experiments.
2.9. Western blot analysis
Cells were collected by centrifugation at 12 000 rpm for 10 min, and
then the pellets were resuspended in lysis buﬀer (1% Nonidet P-40,
1 mmol/L, 40 mmol/L Tris hydrochloride, pH 8.0, and 150 mmol/L
NaCl) at 4 C for 30 min. Protein concentrations were determined
using BCA protein assay (Pierce) examined with Microplate Reader
(Bio-Tek, Elx800) at 570 nm. Cell lysates (80 lg protein per lane) cells
were lysed in SDS/PAGE sample buﬀer with complete protease inhib-
itors (Roche), separated by SDS/PAGE and transferred to PVDF
(Amersham Biosciences). Blot were incubated with PCNA(sc-56) (San-
ta Cruz Biotechnology) which is mouse antibody and p21Waf/Cip(H-
164, sc-756), p27Kip1(c-19), p-ERK1/2(CST), ERK1/2(CST) and
Cdk2(M2, sc-163) (Santa Cruz Biotechnology) which are rabbit anti-
bodies; Followed by a horseradish peroxidase conjugated anti-mouse
or anti-rabbit antibody (Santa Cruz Biotechnology), developed by
using Supersignal chemiluminescence reagents (Pierce), and exposed
to X-ray ﬁlm.3. Results
3.1. Molecular characterization of LRRC4
As shown in Fig. 1A, the structural properties of LRRC4
suggest it is a potential type Ia membrane protein of the
LRR superfamily [9,14]. LRRC4 contains two hydrophobic
segments at its N-terminus and C-terminus for sequences rep-
resenting a putative signal peptide with a possible cleavage site
between amino acid 41–42 and a transmembrane region,
respectively. Following the signal peptide, the LRR region
consists of nine and a half times tandem arrays of LRRs
accompanied by typical amino-ﬂanking (AF) and carboxy-
ﬂanking (CF) clusters [9]; the cysteine-rich clusters ﬂanking
the LRRs are highly conserved in many LRR proteins which
function as adhesion proteins and receptors (Fig. 1B and C)
[9,14]. Among these LRRC4 shares the highest homology
(up to 55% identity and 71% similarity) with NGL-1 (Netrin-
G1 ligand) [15]. Adjacent to the carboxy-ﬂanking region, one
C2-type Ig-like domain is identiﬁed. Similar to the other do-
mains, alignment of LRRC4 with the members of Ig superfam-
ily revealed the Ig-like domain in LRRC4 showed highest
homologue with NGL-1 (up to 56% identity and 72% similar-
ity) [15]. Furthermore, it is homologous to that domain in neu-
ron-glia cell adhesion molecule (NCAM) [16], with 42%
identity and 48% similarity. LRRC4 also shares up to 39%
identities and 54% similarities with three Ig-like domains of
Fig. 1. Molecular characterization of LRRC4. (A) The top is deduced amino acid sequence of LRRC4. The boxed sequences corresponding to the
putative N-terminal signal peptide and C-terminal transmembrane region. The nine and a half conserved LRRs are indicated by Roman numerals
and alternating shadow, all the residues of the LRR backbone in black squares. The ﬂanking sequence is in bold type. An IgC2 like domain is in
black box. The bottom is the consensus sequence comparisons between LRR motif of LRRC4 and a typical LRR. (B, C) Comparisons of amino- and
carboxy-terminal LRR-ﬂanking regions from LRRC4 with several members of LRR superfamily. Consensus residues are shadowed in black,
conserved residues are shaded in grey.
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role in axon guidance [17,18].
3.2. Membrane localization of LRRC4
To provide further support on the subcellular localization of
LRRC4, we transiently transfected U251MG cells with
pEGFP-C1-LRRC4, a construct containing LRRC4 CDS re-
gion in the COOH terminus of GFP. Transfected cells were ob-served under ﬂuorescent microscope. As shown in Fig. 2, the
cell membrane localization of LRRC4 was visualized 24 h after
transfection, indicating that the human LRRC4 encodes a
membrane-bound LRR protein.
3.3. The distribution of LRRC4 in the tissues
To systematically examine the distributions of LRRC4
mRNA in human and mouse normal tissues, we performed
Fig. 4. RT-PCR analysis of LRRC4 mRNA in developing brain of
BALB-C mouse.
Fig. 2. Subcellular localization of LRRC4 in U251MG cells. The left
picture indicates U251MG cells transfected with pEGFP-C1; the right
picture indicates U251MG cells transfected with pEGFP-C1-LRRC4.
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in Fig. 3, LRRC4 mRNA displayed a brain-speciﬁc expression
pattern both in human and mouse. Three dot nine kb tran-
script for LRRC4 was detected in human brain, while not in
the other ﬁfteen normal tissues including heart, placenta, lung,
liver, skeletal muscle, kidney, pancreas, spleen, thymus, pros-
tate, testis, uterus, small intestine, colon, and peripheral blood
leukocyte (Fig. 3A (top)). The expression of LRRC4 in mouse
tissues including stomach, skeletal muscle, kidney, liver, heart,
spleen, uterus, brain and lung, was similar to that in human tis-
sues (Fig. 3A (bottom)).
To further characterize the distribution of LRRC4 expres-
sion in brain, Northern blot and in situ hybridization were
performed. The result showed that LRRC4 expression in hu-
man brain was limited to the following areas such as cerebel-
lum, cerebral cortex, occipital pole, frontal lobe, temporal
lobe, and putamen, of which, cerebellum accounted for the
highest level. In medulla and spinal cord, LRRC4 was notFig. 3. Tissue distributions of LRRC4mRNA in human and mouse. (A) Dist
PCR. The upper picture indicates human tissues; the lower picture indica
conﬁrmed by b-actin or GAPDH. (B) Expression of LRRC4 mRNA in hum
human brain by Northern blot. In all cases, RNA integrity and equal loadi
LRRC4 in mouse brain by in situ hybridization. Picture B and D are magniﬁ
indicates neuron; arrow indicates neuroglia-like cell.detected (Fig. 3B (top)). In mouse brain, LRRC4 displayed
similar expression proﬁle. Interestingly, the positive signals
were observed predominantly in neuroglia-like cell (Fig. 3B
(bottom)).ribution of LRRC4mRNA in normal tissues by Northern blot and RT-
tes mouse tissue. In all cases, RNA integrity and equal loading are
an and mouse brain. The upper picture shows expression of LRRC4 in
ng are conﬁrmed by GAPDH. The lower picture shows expression of
ed images of that in the inset in picture A and C, respectively. Triangle
3678 Q. Zhang et al. / FEBS Letters 579 (2005) 3674–36823.4. Expression of LRRC4 in developing brain of mouse
Sequence character of human LRRC4 implies this gene may
be involved in brain development. To test this notion, total
RNA from diﬀerent stage of developing mouse brain was ex-
tracted and reversely transcribed into cDNA. RT-PCR was
carried out to examine the expression of LRRC4 mRNA.
The result indicated that expression of LRRC4 was higher in
postnatal brain than that in embryonic stage (Fig. 4). In the
early of the brain development, the expression of LRRC4 in-
creased with the age, it reached peaked at P2 and then main-
tained at a relatively stable level, suggesting a possible role
of LRRC4 in brain development.
3.5. Diﬀerential expression of LRRC4 in normal and tumor
tissue biopsies
In order to investigate the possible role of LRRC4 in pri-
mary tumorigenesis, LRRC4 mRNA expression in 448 speci-
mens was examined by in situ hybridization on multi-tumor
tissue microarrays. Fig. 5A showed that expression of LRRC4
was brain-speciﬁc and signiﬁcant down-regulated in brain tu-
mor biopsies. Northern blot also showed that LRRC4 expres-
sion similar to that by in situ hybridization (Fig. 5B).
3.6. Generation of U251MG Tet-on cell lines expressing LRRC4
To determine the possible mechanism of LRRC4 for inhibit-
ing tumorigenicity, ﬁrst we established the stable U251MG
Tet-on cell line and the doxycycline-inducible cell lines
U251MG Tet-on with plasmid pTRE-2hyg-LRRC4, 80 cell
clones were screened by luciferase expressing system measured
by scintillation counting. The results indicated the 22nd cloneFig. 5. Expression of LRRC4mRNA in 14 sorts human normal and neoplast
and U251MG cell line by Northern blot. (A) Expression of LRRC4 mRNA i
on multi-tumor tissue microarrays including 448 specimens. LRRC4 displa
tumor biopsies. (C) LRRC4 displayed signiﬁcant down-regulation in gliomawas lower background and more favorable inductivity than the
others, moreover, the dose–eﬀect curve and time–eﬀect curve
all showed that expression of the 22nd clone was highest at
the dosage of 2.0 mg/L doxycycline at 36 h (data not shown).
Therefore, this clone was chosen to construct dual stable
U251MG Tet-on cell line expressing LRRC4. Twenty cell lines
stably transfected pTRE-2hyg-LRRC4 were obtained. RT-
PCR and Northern blot conﬁrmed that there was a signiﬁcant
diﬀerence in the expression of LRRC4 in the stable cell lines
P27 and P28 in the absence and presence of doxycycline. High-
er expression of LRRC4 was indicated at the dosage of 2.0 mg/
L doxycycline at 24 h (Fig. 6).
3.7. Cell-cycle kinetics of U251MG Tet-on cell lines expressing
LRRC4
To test whether the decreased tumorigenesis and cell prolif-
eration of U251MG reﬂected a block at a speciﬁc stage in the
cell cycle or apoptosis product, we analyzed their DNA con-
tent by PI staining and ﬂow cytometry. Results showed an in-
creased fraction of cells in the G1-phase and subsequent
decrease in both S- and G2/M-phase in U251MG Tet-
on-LRRC4 (P27, P28) cell lines after induction by doxycycline
(Fig. 7A). But results failed to reveal signiﬁcant diﬀerences in
apoptosis (data not shown). This data suggested that
LRRC4-mediated growth inhibition may result from a delay
in G1/S transition rather than from apoptosis.
Further to analyze the change of cyclins by ﬂow cytometry,
we found that cyclinD1 and cyclinE was increased, but cyclinA
was markedly decreased when the U251MG Tet-on-LRRC4
positive clones (P27 and P28) were exposed to doxycyclineic tissues and expression of LRRC4mRNA in typical samples of glioma
n 14 sorts human normal and neoplastic tissues by in situ hybridization
yed brain-speciﬁc expression and signiﬁcant down-regulation in brain
biopsies and expressed deletion in U251MG cell line.
Fig. 6. Generations of U251MG Tet-on cell lines expressing LRRC4.
Construction of stable U251MG Tet-on cell lines expressing LRRC4.
20 cell lines stably transfected pTRE-2hyg-LRRC4 cultured with or
without doxycycline was analyzed by RT-PCR (not shown) and
Northern blot, P27 and P28 were lower basal expression and higher
induction with doxycycline. The dose–eﬀect curve and time–eﬀect
curve showed that expression of the P27 and P28 clones were highest
when the clones were induced by 2.0 mg/L doxycycline at 24 h.
Fig. 7. Alteration of cell cycle kinetics in LRRC4 cell lines. (A)
Compared with control cell line (U251MG), P27 and P28 all showed a
marked delay in accumulation at the G0/G1 phase in the presence of
doxycycline (2.0 mg/L). (B) Cyclin analysis showed that cyclinD1 and
cyclinE was increased, while cyclinA was markedly decreased when the
U251MG Tet-On-LRRC4 positive clones (P27 and P28) induction
with doxycycline.
Fig. 8. Dynamic expression of cell cycle associated molecules regu-
lated by LRRC4. Western blot analysis identities that LRRC4 cause a
durative upregulation in p21Waf/Cip and p27Kip1 and resulted in a
sequential time-dependent change in the molecules associated with cell
cycle progression and cell proliferation, such as Cdk2 PCNA and
ERK1/2.
Q. Zhang et al. / FEBS Letters 579 (2005) 3674–3682 3679(Fig. 7B). Together, the data indicated that LRRC4 induced a
delay of cell cycle in late G1 phase.
3.8. Expression alterations of cell cycle associated molecules
regulated by LRRC4
To seek for possible factors involved in a delay in late G1
phase in U251MG, we examined the dynamic changes of cell
cycle-related molecules in by Western blot (Fig. 8). We found
that in the U251MG Tet-on-LRRC4 cell treated with doxycy-
cline, the expression of Cdk2 was decreased at 4 h and more
apparently at 8 h. LRRC4 cause a durative upregulation in
expression of p21Waf/Cip and p27Kip1 at the U251MG Tet-on-
LRRC4 cell treated with doxycycline from 4 h up to 36 h. As
proliferating-cell nuclear antigen (PCNA) and ERK1/2, which
mediated, respectively, DNA replication and cell proliferation,
are regulated by the CDKs inhibitors p21Waf/Cip and p27Kip1,
we investigated the changes in PCNA expression and the
Erk1/2 phosphorylation. The results indicated that LRRC4
cause a downregulation in PCNA expression at the
U251MG Tet-on-LRRC4 cell treated with doxycycline from
16 to 24 h, the reduction was more apparent at 20 h; Similar
to PCNA, the Erk1/2 phosphorylation state was downregula-
tion from 8 to 24 h, more apparent at 12 h.
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LRRC4 is a novel brain-speciﬁc gene on 7q31-32, encoding
a putative type Ia transmembrane protein containing nine
and a half LRRs, a single C2-type Ig-like domain, and is con-
sidered to be a new member of the LRR and Ig superfamily.
LRRC4 predicted protein structure and its similarity to ner-
vous system-expressed LRR proteins such as NGL-1 [15]
and LRRN6A [19], suggesting that it is a novel gene of rele-
vance in the molecular and cellular neurobiology of verte-
brates. LRR is a repetitive motif made up of several copies
of amino acid residues with the conserved sequence
LxxLxxLxLxxNxLxxLxxxxFxx. This motif is thought to be
involved in highly speciﬁc protein–protein interactions or cell
adhesion [9,10]. The Ig C2 has also been implicated in adhe-
sion or binding to other proteins [20,21]. These motifs can be
adapted to speciﬁc functions by variation and repetition or by
combination with other motifs. Members containing both
LRR and the Ig C2 domain have only been cloned from a
few genes such as Trk receptors [22–24], LIG-1 [25] and ISLR
[26]. Most of these proteins play signiﬁcant roles in diﬀeren-
tiation and development of tissues such as the CNS. Trk
receptors are transmembrane glycoproteins containing LRR,
Ig C2, and a cytosolic tyrosine kinase domain [27]. The
LRR and Ig-like domain of Trk receptors have been indi-
cated as being important for speciﬁc ligand binding [28–30].
NGL-1 (Netrin-G1 ligand), a novel transmembrane protein
containing LRR and Ig C2 domains, can promote the out-
growth of thalamocortical axon via speciﬁcally interacting
with netrin-G1 through its LRR region [15]. NCAM, an
adhesion molecule containing Ig C2 domain [16], is also able
to stimulate neuronal outgrowth and diﬀerentiation by acti-
vating some signaling pathways [31]. These ﬁndings suggested
that LRRC4 might play an essential role in the development
and maintenance of normal function in the nervous system.
In support of this notion, we found the distribution of
LRRC4 displays a brain-speciﬁc pattern both in normal hu-
man and mouse tissues. Furthermore, LRRC4 expression
exhibited a development-regulated pattern in diﬀerent stage
of brain.
Recently, LRR proteins have also been implied to be in-
volved in nervous system tumors. Overexpression of Pur (al-
pha), a protein containing three basic aromatic (class I) and
two acidic leucine-rich (class II) repeats in the central region,
has been found to be able to suppress proliferation of a variety
of transformed tumor cells including human glioblastoma
through the region spanning the ﬁrst class II repeat and the
second class I repeat [32]. It has also been reported that activa-
tion of Trk A receptor can lead to extensive apoptosis in
medullblastoma cells [33,34]. LGI-1 is rearranged and down-
regulated in malignant brain tumors [35]. Our data is consis-
tent with above reports by showing the absence or very low
level of LRRC4 in primary brain tumors (Fig. 5), also conﬁrm-
ing a previous study which suggests LRRC4 has the potential
of suppressing U251MG tumorigenesis and cell proliferation
[8]. Taken together, we think that LRRC4might act as a recep-
tor for a certain trophic factor or for an adhesion molecule
contributing to maintenance of normal brain function and
inhibition of tumorigenesis.
Inducibility is desirable for gene function study, since it
provides a more ﬂexible control of gene expression [36,37].
In the present study, using two stable U251MG Tet-on-LRRC4 cell lines we investigated the potential molecular
mechanism of LRRC4 inhibiting tumorigenesis. Cell cycle
studies indicated that the proliferation defect resulted from
a G1/S delay in cell-cycle kinetics. The cyclin analysis led to
the speculation that the delay in G1/S transition might be in-
duced by interrupting the connection between cyclin E and
cyclin A.
The eukaryotic cell cycle transition is regulated by the action
of the cyclin-dependent kinases (CDKs), cdk subunit and a
regulatory cyclin subunit [38,39]. CyclinE is a necessary and
rate limiting for the passage of mammalian cells through the
G1 phase of the cell cycle, which is expressed in mid G1 phase
and associates with Cdk2 kinase [40], while Cdk2 accelerates
G1/S transition and S phase progression by combining cyclinE
and activating cyclinA transcription [41]. In addition, mamma-
lian cell cycle is also controlled by antimitogenic signals med-
iated by the members of p21 family, such as p21Waf1/Cip1 and
p27Kip1. The protein p21Waf1/Cip1, induced by the tumor-sup-
pressor protein p53, interacts with and inhibits two diﬀerent
targets essential for cell-cycle progression. One of these is the
cyclin-CDK family of kinases and the other is the essential
DNA replication factor, PCNA [42–45]. p21Waf1/Cip1 shows
to play an essential role in G1 arrest by inhibiting cyclinE-
cdk2 activities [46]; similarly, p27Kip1 blocks cyclinE-depen-
dent transactivation of cyclinA gene expression causing G1
arrest [38]. Impairment of a growth stimulatory signaling
pathway (such as erbB1, raf and MAPK) has been shown to
be induced by p21Waf1/Cip1 and p27Kip1 [47–50]. Many antipro-
liferative factors mediated an arrest in the G0/G1 cell-cycle
phase by induced expression p21Waf1/Cip1 and p27Kip1, result-
ing in Cdk2 kinase activity inhibition [51–56]. Therefore, in
order to characterize the molecular pathway by which LRRC4
mediates its antiproliferative action upon the U251MG cell
line, a complete analysis of the cell cycle events in these cells
both prior to and consequent of the initial observed G1 arrest
at 36 h was performed (Fig. 8). The ﬁnding that after overex-
pression of LRRC4, the expressions of p21Waf1/Cip1 and
p27Kip1 were upregulated following by the downregulation of
Cdk2, PCNA and the Erk1/2 phosphorylation state, suggests
an involvement of p21Waf1/Cip1 and p27Kip1 in the regulation
of Cdk2, PCNA and the Erk1/2 phosphorylation state. There-
fore, it is conceived that the increase in p21Waf1/Cip1 and
p27Kip1 expressions and the reduction in Cdk2 kinase activity
might be the mechanism responsible for the cell cycle delay
in G1/S phase during the early phase of tet-regulatable LRRC4
treated with doxycycline. The reduction of PCNA and the
ERK1/2 phosphorylation state would appear to be a conse-
quence of the upregulations of p21Waf1/Cip1 and p27Kip1
and the reduction of Cdk2 activity, and a method of maintain-
ing the LRRC4-induced delay in G1/S transition. Taken
together, the data implies that LRRC4 is a membrane protein
and a trigger for the late G1 delay through a cascade of molec-
ular expression alterations inhibiting DNA replication and
MAPK pathway.
In conclusion, we characterized the expression and function
of LRRC4, a brain-speciﬁc novel member of LRR superfamily,
by showing LRRC4 as a negative regulator of cell growth and
underscore a link between above-mentioned cyclins, cyclin-
associated molecules and tumorigenicity. This data may serve
as a spring board for further study of the role of LRRC4 in
maintenance of normal function and inhibition of tumorigen-
esis in the central nervous system.
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